Valeant adds cash and a CVR to its Allergan bid, but will that $50M-plus be enough?
28.05.2014 / Fierce Pharma
As promised, Valeant has raised its original $47 billion offer for Allergan. And as expected, that offer comprises more cash than the original. Whether it'll be enough to win over the California company? That remains to be seen.